AAPL VS JAGX Stock Comparison

Performance

AAPL
100/100

AAPL returned 13.51% in the last 12 months. Based on SPY's performance of -13.31%, its performance is above average giving it a score of 100 of 100.

JAGX
10/100

JAGX returned -96.90% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AAPL
78/100

38 analysts offer 12-month price targets for AAPL. Together, they have an average target of 190.63, the most optimistic target put AAPL at 240 within 12-months and the most pessimistic has AAPL at 110.

JAGX
75/100

1 analysts offer 12-month price targets for JAGX. Together, they have an average target of 0, the most optimistic target put JAGX at 0 within 12-months and the most pessimistic has JAGX at 0.

Sentiment

AAPL
70/100

AAPL had a bullish sentiment score of 70.31% across Twitter and StockTwits over the last 12 months. It had an average of 3,037.82 posts, 116,437.71 comments, and 721,824.29 likes per day.

JAGX
70/100

JAGX had a bullish sentiment score of 69.95% across Twitter and StockTwits over the last 12 months. It had an average of 251.11 posts, 260.33 comments, and 684.97 likes per day.

Technicals

AAPL
18/100

AAPL receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

JAGX
21/100

JAGX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

AAPL
100/100

AAPL has missed earnings 1 times in the last 20 quarters.

JAGX
10/100

JAGX has missed earnings 12 times in the last 20 quarters.

Profit

AAPL
76/100

Out of the last 20 quarters, AAPL has had 20 profitable quarters and has increased their profits year over year on 10 of them.

JAGX
10/100

Out of the last 20 quarters, JAGX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

AAPL
45/100

AAPL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

JAGX
54/100

JAGX has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

Dividend

AAPL
50/100

AAPL's most recent dividend was $0.18 per share, based on a share price of $168.22. It was a payout ratio of 24.99% compared to their total earnings.

JAGX

"Dividend" not found for JAGX

All score calculations are broken down here to help you make more informed investing decisions

Apple Inc. Summary

Nasdaq / AAPL

Technology

Consumer Electronics

Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.

Jaguar Health, Inc. Summary

Nasdaq / JAGX

Healthcare

Biotechnology

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Power up your portfolio